367 related articles for article (PubMed ID: 26751003)
1. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
Merkel EC; Mitchell SA; Lee SJ
Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
[TBL] [Abstract][Full Text] [Related]
2. Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population.
Vasconcellos de Souza C; Vigorito AC; Miranda ECM; Garcia C; Rensi Colturato VA; Mauad MA; Rodrigues Moreira MC; da Silva Bouzas LF; Lermontov S; Hamerschlak N; Rodrigues M; Carlos de Almeida Barros J; Chiattone R; Lee SJ; Flowers MED
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1313-1318. PubMed ID: 27058616
[TBL] [Abstract][Full Text] [Related]
3. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
4. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.
Lee Sk; Cook EF; Soiffer R; Antin JH
Biol Blood Marrow Transplant; 2002; 8(8):444-52. PubMed ID: 12234170
[TBL] [Abstract][Full Text] [Related]
7. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.
Herzberg PY; Heussner P; Mumm FH; Horak M; Hilgendorf I; von Harsdorf S; Hemmati P; Rieger K; Greinix H; Freund M; Lee SJ; Holler E; Wolff D
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1707-17. PubMed ID: 20541028
[TBL] [Abstract][Full Text] [Related]
8. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
Baird K; Steinberg SM; Grkovic L; Pulanic D; Cowen EW; Mitchell SA; Williams KM; Datiles MB; Bishop R; Bassim CW; Mays JW; Edwards D; Cole K; Avila DN; Taylor T; Urban A; Joe GO; Comis LE; Berger A; Stratton P; Zhang D; Shelhamer JH; Gea-Banacloche JC; Sportes C; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):632-9. PubMed ID: 23340040
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
10. Development and psychometric testing of a pediatric chronic graft-versus-host disease symptom scale: protocol for a two-phase, mixed methods study.
Mitchell SA; Hunter R; Fry A; Pavletic SZ; Widemann BC; Wiener L
Front Psychol; 2023; 14():1243005. PubMed ID: 38259542
[TBL] [Abstract][Full Text] [Related]
11. Personality influences quality-of-life assessments in adult patients after allogeneic hematopoietic SCT: results from a joint evaluation of the prospective German Multicenter Validation Trial and the Fred Hutchinson Cancer Research Center.
Herzberg PY; Lee SJ; Heussner P; Mumm FH; Hilgendorf I; von Harsdorf S; Hemmati P; Rieger K; Greinix HT; Freund M; Holler E; Wolff D
Bone Marrow Transplant; 2013 Jan; 48(1):129-34. PubMed ID: 22609882
[TBL] [Abstract][Full Text] [Related]
12. Reliability and Validity of the Modified 7-Day Lee Chronic Graft-versus-Host Disease Symptom Scale.
Teh C; Onstad L; Lee SJ
Biol Blood Marrow Transplant; 2020 Mar; 26(3):562-567. PubMed ID: 31759158
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
14. Symptoms, Cytokines, and Quality of Life in Patients Diagnosed with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation.
Lynch Kelly D; Lyon DE; Ameringer SA; Elswick RK
Oncol Nurs Forum; 2015 May; 42(3):265-75. PubMed ID: 25901378
[TBL] [Abstract][Full Text] [Related]
15. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
[TBL] [Abstract][Full Text] [Related]
16. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease.
Kurosawa S; Oshima K; Yamaguchi T; Yanagisawa A; Fukuda T; Kanamori H; Mori T; Takahashi S; Kondo T; Kohno A; Miyamura K; Umemoto Y; Teshima T; Taniguchi S; Yamashita T; Inamoto Y; Kanda Y; Okamoto S; Atsuta Y
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1749-1758. PubMed ID: 28669922
[TBL] [Abstract][Full Text] [Related]
17. Verification of the new grading scale for ocular chronic graft-versus-host disease developed by the German-Austrian-Swiss consensus conference on chronic GVHD.
Blecha C; Wolff D; Holler B; Holler E; Weber D; Vogt R; Helbig H; Dietrich-Ntoukas T
Ann Hematol; 2016 Feb; 95(3):493-9. PubMed ID: 26659079
[TBL] [Abstract][Full Text] [Related]
18. Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease.
Cardones AR; Sullivan KM; Green C; Chao NJ; Rowe-Nichols K; Bañez LL; Burton CS; Horwitz ME; Long GD; Rao CL; Sarantopoulos S; Sidhu-Malik N; Sung AD; Hall RP
JAMA Dermatol; 2019 Jul; 155(7):833-837. PubMed ID: 30994873
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.
Palmer J; Williams K; Inamoto Y; Chai X; Martin PJ; Tomas LS; Cutler C; Weisdorf D; Kurland BF; Carpenter PA; Pidala J; Pavletic SZ; Wood W; Jacobsohn D; Arai S; Arora M; Jagasia M; Vogelsang GB; Lee SJ
Biol Blood Marrow Transplant; 2014 Mar; 20(3):337-44. PubMed ID: 24315845
[TBL] [Abstract][Full Text] [Related]
20. Psychological and physical function in allogeneic hematopoietic cell transplant survivors with chronic graft-versus-host disease.
Hansen JL; Juckett MB; Foster MA; Rumble ME; Morris KE; Hematti P; Costanzo ES
J Cancer Surviv; 2023 Jun; 17(3):646-656. PubMed ID: 36917433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
